Clinical evaluation of RSA pacing in post-surgery patients

RSA起搏在术后患者中的临床评价

• 批准号: 10021677
• 金额: $ 54.86万
• 依托单位: CERYX MEDICAL LIMITED
• 依托单位国家: 英国
• 项目类别: Investment Accelerator
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=10021677
• 关键词: Clinical; evaluation; RSA; pacing; post

Patients who undergo cardiac surgery often find their hearts struggle to supply enough blood to the body during the recovery period post-surgery. Ceryx have developed a unique pacing device which is able to boost the performance of the heart while also reducing the workload on the heart, which can help the heart to heal. In this project, Ceryx will trial its new technology in patients following cardiac surgery.Ceryx will interface their technology to an existing temporary pacing device which patients are routinely fitted with during surgery. Driven by Ceryx's technology this device will then deliver the therapeutic pacing to the heart until the patient is ready to be discharged, usually after about a week. During this time the patient's heart will be monitored for improvements in function and structure. The patients' ability to exercise will also be assessed, along with their symptoms and quality of life.If the trial is successful, this project will have accelerated the development of Ceryx's technology considerably and it may be that a new therapy for patients recovering from cardiac surgery could be on the market in 1-2 years.

接受心脏手术的患者经常发现他们的心脏在术后恢复期间难以向身体提供足够的血液。 Ceryx 开发了一种独特的起搏装置，能够提高心脏的性能，同时减少心脏的工作负荷，从而帮助心脏愈合。在该项目中，Ceryx 将在心脏手术后的患者中试验其新技术。Ceryx 将其技术与患者在手术期间常规安装的现有临时起搏装置连接。在 Ceryx 技术的驱动下，该设备将向心脏提供治疗起搏，直到患者准备好出院（通常在大约一周后）。在此期间，将监测患者心脏的功能和结构的改善情况。患者的运动能力以及他们的症状和生活质量也将受到评估。如果试验成功，该项目将大大加速 Ceryx 技术的发展，并且可能为心脏病康复患者提供一种新的治疗方法。手术可能会在 1-2 年内上市。